LIPOCINE INC (LPCN)

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 17 full-time employees. The company went IPO on 2014-03-21. The firm is focused on leveraging its Lip’ral platform to develop differentiated products through oral delivery. The company has a portfolio of differentiated product candidates that target high unmet needs for neurological and psychiatric Central Nervous System (CNS) disorders, liver diseases, and hormone supplementation for men and women. The firm's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its clinical development pipeline candidates include LPCN 1154 for postpartum depression (PPD), LPCN 2101 for epilepsy, and LPCN 1148 an androgen therapy for the management of cirrhosis. The firm is focused on exploring partnering opportunities for LPCN 1107, its candidate for the prevention of preterm birth; LPCN 1148, for the management of decompensated cirrhosis; LPCN 1144, its candidate for the treatment of non-cirrhotic NASH, and LPCN 1111.

Company Info

LIPOCINE INC

675 S Arapeen Dr Ste 202

Salt Lake City UTAH 84108

P: 18019947383

CEO: Mahesh V. Patel

Employees: 17

Website: https://www.lipocine.com/